Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Equivalence of Budesonide/Albuterol MDI HFO vs HFA in Asthma
NCT06502366Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2024
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial of budesonide and albuterol dry powder inhaler in asthma (3 arms), sponsored by AstraZeneca. Primary endpoint: Change from baseline in peak FEV1 in 0-60 minutes after dosing at Day 29. Started Jul 2024; status: completed.
02
Drugs
budesonidealbuterol dry powder inhaler
03
Conditions
asthma
Beyond the preview
Go deeper on NCT06502366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06502366.